LILRB1 and neoplasm: Nonetheless, it is possible that optimal clinical responses may require a combination therapy of multiple antibodies blocking a wider variety of inhibitory receptors expressed on NK cells, such as KIR3DL family members, CD94/NKG2A, and ILT2/LIR-1/CD85j, as well as the addition of an ADCC targeting mAb to stimulate tumor-specific cytotoxicity, as demonstrated by the in vitro studies of Binyamin et al. described earlier (80).